{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T12:57:01Z","timestamp":1780059421800,"version":"3.54.0"},"reference-count":23,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T00:00:00Z","timestamp":1756080000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100011776","name":"Instituto Portugu\u00eas de Oncologia do Porto","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011776","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Nephrol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>High-dose methotrexate (HDMTX) is central to treating primary central nervous system lymphoma but carries a risk of acute kidney injury (AKI), which can delay methotrexate (MTX) clearance and increase toxicity. Glucarpidase is the treatment of choice for MTX toxicity, but limited access in many countries may necessitate alternatives. We present the first reported adult case of combined high-flux hemodialysis (HFHD) and HA230 hemoadsorption for MTX clearance.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case summary<\/jats:title><jats:p>A 66-year-old woman with newly diagnosed primary central nervous system lymphoma began induction chemotherapy including HDMTX. Forty-eight hours post-infusion, she developed KDIGO stage 3 AKI, with plasma MTX levels of 26.278 \u00b5mol\/L despite maintained urine output and early supportive measures. On Day 3, MTX levels remained elevated at 15.567 \u00b5mol\/L, accompanied by severe metabolic alkalosis. She was admitted to intensive care, where she underwent HFHD combined with post-filter HA230 hemoadsorption, followed by intravenous glucarpidase as soon as it became available. A second extracorporeal session occurred 48 hours later. MTX levels decreased by 91.93% (estimated elimination half-life \u2248 0.83 hours) and 71.02% (half-life \u2248 2.12 hours) after the first and second sessions, respectively. No significant rebound in MTX levels or dialysis-related complications occurred. The patient recovered renal function and completed further treatment without MTX.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>This case demonstrates the effectiveness of combined HFHD and HA230 hemoadsorption as a bridging or alternative strategy when glucarpidase is delayed or unavailable. While evidence remains limited, it supports further investigation into extracorporeal MTX removal and contributes to the evolving field of Onconephrology.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fneph.2025.1644079","type":"journal-article","created":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T04:10:36Z","timestamp":1756095036000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Case Report: Effective methotrexate removal by combined hemodialysis and polymeric resin hemoadsorption"],"prefix":"10.3389","volume":"5","author":[{"given":"Maria Rita","family":"Dias","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Nicolau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugo","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9rgio","family":"Chacim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gon\u00e7alo","family":"de C\u00e2mara Negalha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 M\u00e1rio","family":"Mariz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Maximino","family":"Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,8,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.11.010","article-title":"EHA and ESMO Guidelines Committees. Primary central nervous system lymphomas: EHA-ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"14","author":"Ferreri","year":"2024","journal-title":"Ann Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2015-0164","article-title":"Preventing and managing toxicities of high-dose methotrexate","volume":"21","author":"Howard","year":"2016","journal-title":"Oncologist"},{"key":"B3","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1634\/theoncologist.11-6-694","article-title":"Understanding and managing methotrexate nephrotoxicity","volume":"11","author":"Widemann","year":"2006","journal-title":"Oncologist"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.08030621","article-title":"Extracorporeal treatment for methotrexate poisoning: systematic review and recommendations from the EXTRIP workgroup","volume":"17","author":"Ghannoum","year":"2022","journal-title":"Clin J Am Soc Nephrol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.25.4540","article-title":"Glucarpidase, leucovorin, and thymidine for high-dose methotrexate-induced renal dysfunction: clinical and pharmacologic factors affecting outcome","volume":"28","author":"Widemann","year":"2010","journal-title":"J Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.12-11-1299","article-title":"Glucarpidase (carboxypeptidase g2) intervention in adult and elderly cancer patients with renal dysfunction and delayed methotrexate elimination after high-dose methotrexate therapy","volume":"12","author":"Schwartz","year":"2007","journal-title":"Oncologist"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1177\/1078155215594417","article-title":"Evaluation of incidence and risk factors for high-dose methotrexate-induced nephrotoxicity","volume":"22","author":"Wiczer","year":"2016","journal-title":"J Oncol Pharm Pract"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.757464","article-title":"The role of genetic polymorphisms in high-dose methotrexate toxicity and response in hematological Malignancies: A systematic review and meta-analysis","volume":"12","author":"Song","year":"2021","journal-title":"Front Pharmacol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1983.1.3.208","article-title":"Methotrexate-induced renal impairment: clinical studies and rescue from systemic toxicity with high-dose leucovorin and thymidine","volume":"1","author":"Abelson","year":"1983","journal-title":"J Clin Oncol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1634\/theoncologist.2017-0243","article-title":"Consensus guideline for use of glucarpidase in patients with high-dose methotrexate induced acute kidney injury and delayed methotrexate clearance","volume":"23","author":"Ramsey","year":"2018","journal-title":"Oncologist"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1177\/10781552211052564","article-title":"Effective elimination of high-dose methotrexate by repeated hemodiafiltration and high-flux hemodialysis in patients with acute kidney injury","volume":"28","author":"Sakran","year":"2022","journal-title":"J Oncol Pharm Pract"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2025.1495705","article-title":"High-flux hemodialysis as rescue therapy for high-dose methotrexate toxicity: case series and clinical insights","volume":"12","author":"Tome","year":"2025","journal-title":"Front Med (Lausanne)"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1159\/000489921","article-title":"Biocompatibility and cytotoxic evaluation of new sorbent cartridges for blood hemoperfusion","volume":"46","author":"Pomar\u00e8 Montin","year":"2018","journal-title":"Blood Purif"},{"key":"B14","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1159\/000493523","article-title":"A new series of sorbent devices for multiple clinical purposes: current evidence and future directions","volume":"47","author":"Ankawi","year":"2019","journal-title":"Blood Purif"},{"key":"B15","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/s13054-022-04009-w","article-title":"Hemoperfusion: technical aspects and state of the art","volume":"26","author":"Ronco","year":"2022","journal-title":"Crit Care"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1159\/000514135","article-title":"New therapeutic approach to reduce methotrexate toxicity after high-dose chemotherapy in a child with acute lymphocytic leukemia: efficacy and safety of hemoadsorption with HA-230 adsorber","volume":"51","author":"Sazonov","year":"2022","journal-title":"Blood Purif"},{"key":"B17","first-page":"90","article-title":"Esencial en: Purificaci\u00f3n sangu\u00ednea extracorp\u00f3rea por adsorci\u00f3n","author":"Ronco","year":"2024","journal-title":"Int Renal Res Institute Vicenza"},{"key":"B18","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/kisup.2011.32","article-title":"Section 2: AKI definition","volume":"2","author":"Kellum","year":"2011","journal-title":"Kidney Int Suppl"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20255","article-title":"High-dose methotrexate-induced nephrotoxicity in patients with osteosarcoma","volume":"100","author":"Widemann","year":"2004","journal-title":"Cancer"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/s002800050528","article-title":"Methotrexate removal during haemodialysis in a patient with advanced laryngeal carcinoma","volume":"38","author":"Thomson","year":"1996","journal-title":"Cancer Chemother Pharmacol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1360","article-title":"Efficacy of glucarpidase (carboxypeptidase g2) in patients with acute kidney injury after high-dose methotrexate therapy","volume":"34","author":"Widemann","year":"2014","journal-title":"Pharmacotherapy"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.27378","article-title":"Resumption of high-dose methotrexate after acute kidney injury and glucarpidase use in pediatric oncology patients","volume":"118","author":"Christensen","year":"2012","journal-title":"Cancer"},{"key":"B23","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1200\/OP.23.00628","article-title":"Rechallenge with high-dose methotrexate after treatment with glucarpidase in adult patients with lymphoma","volume":"20","author":"Truong","year":"2024","journal-title":"JCO Oncol Pract"}],"container-title":["Frontiers in Nephrology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneph.2025.1644079\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,25]],"date-time":"2025-08-25T04:10:38Z","timestamp":1756095038000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneph.2025.1644079\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,25]]},"references-count":23,"alternative-id":["10.3389\/fneph.2025.1644079"],"URL":"https:\/\/doi.org\/10.3389\/fneph.2025.1644079","relation":{},"ISSN":["2813-0626"],"issn-type":[{"value":"2813-0626","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,25]]},"article-number":"1644079"}}